AEGEAN: A Phase 3 Trial of Neoadjuvant Durvalumab + Chemotherapy Followed by Adjuvant Durvalumab in Patients with Resectable NSCLC

Expert oncologist John Heymach, MD, PhD, reviews data from the phase 3 AEGEAN trial following updates presented at the 2023 AACR annual meeting.

Related Keywords

Neoadjuvant Durvalumab ,John Heymach , ,Adjuvant Durvalumab ,Partnership With ,Nsclc ,Non Small Cell Lung Cancer ,Early Stage Lung Cancer ,Early Stage Nsclc ,Durvalumab ,Durvalumab Therapy ,Overall Survival ,Progression Free Survival ,Event Free Survival ,Pathologic Complete Response ,Pd L1 Expression ,Pd L1 Level ,Adverse Events ,Drug Adverse Event ,Aegean Study ,Aegean Trial ,Efs Bicr ,Dfs Bicr ,Pcr ,Mpr ,